Temple Health Chest Initiative (THCI 2.0)

Part of paid clinical trials in Philadelphia, Pennsylvania.

Sponsor
Temple University
Study ID
NCT06933758
Status
Recruiting
Apply to this trial

Conditions

  • Chronic Obstructive Pulmonary Disease (COPD)

Eligibility Criteria

Sex
ALL
Age
50 Years - 80 Years
Healthy Volunteers
Accepted

Interventions

  • Determine COPD prevalence utilizing spirometry along with CT scans and symptom assessments in the THCI lung cancer screening populatio — DIAGNOSTIC_TEST
    Demonstrate utility of LDCT in COPD characterization Determine exacerbation risk and symptom burden in this patient population Determine the severity of COPD identified through this process Describe phenotypic characteristics including imaging analysis of THCI population Determine the suitability and acceptance of patients to participate in COPD clinical trials Determine the incidence of comorbid lung (ILA, bronchiectasis, pulmonary artery enlargement) and non-lung problems (cardiac and aortic calcifications, osteopenia/osteoporosis and for gut abnormalities) identified by LDCT in a patient population at risk for lung cancer and/or COPD Determine the correlation between clinical measurements and imaging biomarkers

Study Details

Chronic obstructive pulmonary disease is highly prevalent globally, with considerable morbidity and mortality associated. In the US, it is the 4th leading cause of death, as well as contributing to significant costs on healthcare utilization including hospitalization. Population-based screening for COPD has not been recommended by the US Preventative Services Task Force (USPSTF). However, LDCT screening for lung cancer in patients aged 50- 80 with ≥ 20 pack year smoking has been shown to improve survival. COPD is highly prevalent within LCS programs, with estimated rates of obstructive lung function of up to 59% and evidence of emphysema on CT scan in around 70%.

Key Dates

Start date
Feb 28, 2025
Status verified
Jan 2025
Primary completion
May 31, 2026
Completion
Jun 30, 2026

Study Design

Enrollment
1,000 participants (estimated)

Arms

  • Arm: Pulmonary function testing
    If the patient does have airflow obstruction (any severity) they will be contacted to complete additional questionnaires.

Primary Outcome Measure

COPD Prevalence [ Time Frame: 15 months ]

Central Contacts

Locations (1)

FacilityCityStateZIPSite coordinators
Temple University Of the Commonwealth System of Higher EducationPhiladelphiaPennsylvania19140
Lauren Miller, BS
[email protected]
215-707-4821
Stephanie Yerkes, BA
[email protected]
215-707-2357

Find similar trials in Philadelphia, PA

By research site
Temple University Of the Commonwealth System of Higher Education· Philadelphia, PA

Related Studies